Spero Therapeutics — Q2 2026 Earnings Presentation

4 slides from Spero Therapeutics's earnings presentation, Aug 12, 2026

Slide 1: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved Uteb
Slide 2: $105 Million Non-Recourse, Non-Dilutive Royalty Financing
$105 Million Non-Recourse, Non-Dilutive Royalty Financing In July 2026, Spero announced a non-recourse, non-dilutive royalty financing with affiliates of HealthCare Royalty Partners, a business of KKR (HCRx), for $105 million in gross proceeds, in exchange for rights to a portion of the anticipated
Slide 3: About SP001 and Spero Therapeutics; Forward-Looking Statements
SP001 is a third-generation, potential best-in-class, fully humanized, Fc-silent IgG1 monoclonal antibody targeting CD40L, an upstream immune activation signal involved in T-cell, B-cell, antigen-presenting cell, and platelet biology. By blocking CD40L, SP001 has the potential to provide a targeted
Slide 4: Condensed Consolidated Statements of Operations
Spero Therapeutics, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Revenues: Grant revenue $ - 2,387 $ - 3,150 Collaboration revenue - related party - 11,802 25